Sequenom Announces Initial Public Offering of Common Stock

San Diego (PROTEXT) - Sequenom, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a public offering of common stock lead managed by Warburg Dillon Read LLC. Robertson Stephens and SG Cowen will also manage the offering. The underwriters will be granted a 30-day over-allotment option to purchase additional shares of common stock from the company. The company intends to use the proceeds of the offering primarily for general corporate purposes, including hiring of additional sales and customer support personnel, expansion of its facilities, continued development and manufacturing of existing products, research and development of additional products, patent prosecution expenses, working capital and potential acquisitions of products, technologies or companies, and repayment of long- term debt and accrued interest of approximately $4.2 million. Sequenom is a pioneer in the new field of industrial genomics, the large-scale commercial use of the knowledge of DNA variations, or SNPs, for improving health, agriculture and livestock. The company's MassArray system combines proprietary enzymology and bioinformatics in a miniaturized chip-based format with the proven technology of mass spectrometry. The result is a highly accurate, cost-effective and scalable technology capable of high- throughput SNP analysis. The Company is engaged in beta site testing with the U.S. Department of Agriculture, National Institutes of Health, National Cancer Institute and Genzyme Corporation in the U.S. and University of Munster and GLE Medicon in Germany. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State. ots Original Text Service: Sequenom, Inc. Internet: http://www.newsaktuell.de Contact: Abigail Devine of Sequenom, Inc. Investor Relations, (USA) 858-350-0345, adevine@sequenom.com; or Media: Amy Giller of Noonan/Russo Communications, Inc. Financial Communications, (USA) 415-677-4455 ext. 206, a.giller@noonanrusso.com, for Sequenom, Inc. ------- --+---------+---------+---------+---------+---------+--------- News Aktuell Tel.: +49 40 4113-2866 ---------+---------+-------- -+---------+---------+---------+--------- Subscribers please note that material bearing the slug "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" slug. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents. PROTEXT